semaglutide oral half life Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes? Frontiers | Oral delivery of

At RWA Center, the clinical team is committed to helping patients navigate this space with clear information and personalized guidance

Conclusion: Both subcutaneous and oral semaglutide administration could enable the achievement of sufficient glycemic control and weight management without increasing the risk of hypoglycemia, which were effective and safe for the treatment of T2D

Mechanism of Action Tirzepatide: Dual incretin (GIP + GLP-1) enhanced metabolic impact Wegovy: GLP-1 receptor agonist now with higher receptor engagement Weight Loss Outcomes Tirzepatide: ~22% weight reduction in trials Wegovy 7.2 mg: ~2021% weight reduction The efficacy gap is narrowing significantly Cardiometabolic Profile Wegovy: Strong, established cardiovascular outcome data Tirzepatide: Superior glycemic control and insulin sensitivity Safety & Tolerability Both therapies show dose-dependent GI side effects Overall safety profiles remain comparable The Big Picture We are witnessing a shift from: Single-hormone optimization (high-dose semaglutide) to Multi-hormone targeting (tirzepatide) Conclusion While Wegovy is rapidly closing the efficacy gap with dose escalation, Tirzepatide continues to lead as a next-generation metabolic therapy

Compounded medications carry their own separate risks (concentration variability, no FDA review)

If injections are recommended, your team will walk you through the administration process, what to watch for, and how to get the most out of the treatment alongside nutrition and activity guidance